Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBF-015 in Huntington's Disease
NCT06469853Phase 2Completed
- Sponsor
- Medibiofarma
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MBF-015 in Huntington's disease (HD), sponsored by Medibiofarma. Started Feb 2024; status: completed.
02
Drugs
MBF-015
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT06469853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469853.